Diabetes

We recommend

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio -⁠ and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…

5. 12. 2023 Source: Diabetes

Benefit of Empagliflozin in Patients with Chronic Kidney Disease –⁠ Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…

18. 10. 2023 Source: Diabetes

Articles on this topic

konzultace s mladými muži o rakovině prostaty

Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

Albuminuria in patients with type 2 diabetes is associated with a higher risk of…

12. 4. 2022 Source: Diabetes

1 2 3 4 5

E-courses on this topic

Authors: Prof. MUDr. Martin Haluzík, DrSc., prof. MUDr. Vojtěch Melenovský, CSc., prof. MUDr. Vladimír Tesař, DrSc.

Course detail

Diabetes

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Benefit of Empagliflozin in Patients with Chronic Kidney Disease –⁠ Results of the EMPA-KIDNEY Study

Early Detection of Erectile Dysfunction in Men with Type 2 Diabetes

Is it possible to extend the life of diabetics thanks to modern treatment?

Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease

How Diabetes Shortens Life or Mortality of Patients with Type 2 Diabetes

Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?

New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations

Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction

Overlap of SGLT2 Inhibitors from Diabetology to Cardiology

Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment